Cabaletta Bio Inc (CABA)

06:00 AM

Cabaletta Reports Results, Advances Rese-Cel Autoimmune Program - MyChesCo

06:00 AM

01:49 AM

Aug Summary: Can Cabaletta Bio Inc disrupt its industryBuy Signal & Low Drawdown Investment Ideas - baoquankhu1.vn

01:49 AM

Apr 03, 2026

Cabaletta Bio Inc (MEX:CABA) Stock Price, Trades & News - GuruFocus

Apr 03, 2026

Apr 03, 2026

Cabaletta Bio Inc Stock Warning Signs - GuruFocus

Apr 03, 2026

Apr 03, 2026

Cabaletta Bio, Inc. (CABA) Stock forecasts - Yahoo Finance UK

Apr 03, 2026

Apr 03, 2026

Cabaletta Bio, Inc. (CABA) Stock Forecasts - Yahoo! Finance Canada

Apr 03, 2026

Apr 03, 2026

Q1 EPS Estimates for Cabaletta Bio Raised by HC Wainwright - MarketBeat

Apr 03, 2026

Apr 03, 2026

Philly Biotech Co. Develops High-Potential Autoimmune Therapy Breakthrough - Streetwise Reports

Apr 03, 2026

Apr 02, 2026

HC Wainwright Weighs in on Cabaletta Bio Q1 Earnings - MarketBeat

Apr 02, 2026

Apr 02, 2026

CABA Stock Price, Quote & Chart | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill

Apr 02, 2026

Apr 01, 2026

H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo

Apr 01, 2026

Apr 01, 2026

H.C. Wainwright reiterates Cabaletta Bio stock rating at buy By Investing.com - Investing.com Australia

Apr 01, 2026

Apr 01, 2026

H.C. Wainwright reiterates Cabaletta Bio stock rating at buy - Investing.com

Apr 01, 2026

Mar 31, 2026

Cabaletta Bio Inc. (CABA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Mar 31, 2026

Mar 31, 2026

Is Cabaletta Bio Incs ROIC above industry average2026 Weekly Recap & Technical Confirmation Trade Alerts - baoquankhu1.vn

Mar 31, 2026

Mar 31, 2026

Take Profit: What are Cabaletta Bio Incs recent SEC filings showingPortfolio Update Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn

Mar 31, 2026

Mar 29, 2026

Cabaletta Bio (NASDAQ:CABA) Upgraded to "Hold" at Wall Street Zen - MarketBeat

Mar 29, 2026

Mar 28, 2026

Cabaletta Bio, Inc.Common Stock (NQ: CABA - markets.financialcontent.com

Mar 28, 2026

Mar 27, 2026

This Biotech Stock Could Deliver 350% Returns in 12 Months - TradingView

Mar 27, 2026

Mar 27, 2026

Jefferies reiterates Cabaletta Bio stock rating on product profile By Investing.com - Investing.com India

Mar 27, 2026

Mar 27, 2026

Jefferies reiterates Cabaletta Bio stock rating on product profile - investing.com

Mar 27, 2026

Mar 25, 2026

Aug Retail: What is Cabaletta Bio Incs P E ratio telling usPortfolio Profit Report & Capital Efficient Trading Techniques - baoquankhu1.vn

Mar 25, 2026

Mar 24, 2026

Guggenheim Forecasts Strong Price Appreciation for Cabaletta Bio (NASDAQ:CABA) Stock - marketbeat.com

Mar 24, 2026

Mar 24, 2026

Morgan Stanley Cuts Cabaletta Bio (NASDAQ:CABA) Price Target to $13.00 - MarketBeat

Mar 24, 2026

Mar 24, 2026

Analyst Michael Ulz Lowers Price Target for Cabaletta Bio (CABA) to $13 | CABA Stock News - GuruFocus

Mar 24, 2026

Mar 24, 2026

A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $13 to $14 - Moomoo

Mar 24, 2026

Mar 24, 2026

Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Mar 24, 2026

Mar 23, 2026

Jefferies reiterates Buy on Cabaletta Bio stock, $14 target By Investing.com - Investing.com Australia

Mar 23, 2026

Mar 23, 2026

Cabaletta Bio price target lowered to $13 from $14 at Morgan Stanley - TipRanks

Mar 23, 2026

Mar 23, 2026

Jefferies reiterates Buy on Cabaletta Bio stock, $14 target - Investing.com UK

Mar 23, 2026

Mar 23, 2026

William Blair reiterates Outperform on Cabaletta Bio stock By Investing.com - ca.investing.com

Mar 23, 2026

Mar 23, 2026

CABA Advances with Innovative Therapeutic Approaches - GuruFocus

Mar 23, 2026

Mar 23, 2026

Guggenheim raises Cabaletta Bio stock price target on trial progress By Investing.com - Investing.com Australia

Mar 23, 2026

Mar 23, 2026

Guggenheim raises Cabaletta Bio stock price target on trial progress - Investing.com

Mar 23, 2026

Mar 23, 2026

Cabaletta Bio Reports 2025 Financial Results, Highlights Progress on Rese-cel CAR-T Cell Therapy and Upcoming Clinical Milestones - minichart.com.sg

Mar 23, 2026

Mar 23, 2026

Jefferies Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $14 - Moomoo

Mar 23, 2026

Mar 23, 2026

Cabaletta Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com

Mar 23, 2026

Mar 23, 2026

Cabaletta Bio 2024 Annual Report: Engineered T Cell Therapies, Competitive Landscape, and Intellectual Property Strategies for Autoimmune Diseases - Minichart

Mar 23, 2026

Mar 23, 2026

Cabaletta Bio reports Q4 EPS (40c), consensus (47c) - TipRanks

Mar 23, 2026

Mar 23, 2026

Cabaletta Bio (CABA) Exceeds Q4 EPS Expectations - GuruFocus

Mar 23, 2026

Mar 23, 2026

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget

Mar 23, 2026

Mar 23, 2026

Cabaletta Bio Updates Rese-cel Programs and Financial Outlook - tipranks.com

Mar 23, 2026

Mar 23, 2026

Cabaletta Bio (NASDAQ:CABA) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat

Mar 23, 2026

Mar 23, 2026

Cabaletta Bio 10-K: Net loss $167.9M; Cash resources support into Q4 2026 - tradingview.com

Mar 23, 2026

Mar 23, 2026

Cabaletta Bio (NASDAQ: CABA) details 2025 results and advances rese-cel trials - Stock Titan

Mar 23, 2026

Mar 23, 2026

Cabaletta Bio : Corporate Presentation - MarketScreener

Mar 23, 2026

Mar 23, 2026

[10-K] Cabaletta Bio, Inc. Files Annual Report - Stock Titan

Mar 23, 2026